BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/19/2025 5:57:32 AM | Browse: 16 | Download: 79
 |
Received |
|
2024-08-14 02:12 |
|
Peer-Review Started |
|
2024-08-05 18:15 |
|
First Decision by Editorial Office Director |
|
2024-12-11 06:48 |
|
Return for Revision |
|
2024-12-11 06:48 |
|
Revised |
|
2025-02-23 23:23 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-04-16 02:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-04-16 07:32 |
|
Articles in Press |
|
2025-04-16 07:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-05-30 12:57 |
|
Publish the Manuscript Online |
|
2025-11-19 05:57 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Prophylactic role of tixagevimab/cilgavimab for COVID-19 in newly transplanted kidney recipients: Single-center experience and review of literature
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Alissar El Chediak, Dhruv Ahuja, Cassandra Bruns, Rachael Simard, Kellie Spence, Amna Gul, Rachel C Forbes and Beatrice P Concepcion |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Beatrice P Concepcion, Associate Professor, MD, Department of Medicine, Section of Nephrology, University of Chicago, 5841 S. Maryland Ave
MC 5100, Chicago, IL 60637, United States. beatrice.concepcion@bsd.uchicago.edu |
| Key Words |
Pre-exposure prophylaxis; kidney transplant; COVID-19; SARS-CoV-2; tixagevimab/cilgavimab; Early posttransplant period |
| Core Tip |
This study reports on the use of tixagevimab/cilgavimab in newly transplanted kidney recipients. There were no adverse events related to the drug, and a 12.5% breakthrough infection rate, 4.5% hospitalization rate, and no deaths. The results suggest reassuring outcomes in newly transplanted kidney recipients who received tixagevimab/cilgavimab 300 mg/300 mg as prevention for coronavirus disease 2019 during the omicron wave. A systematic literature review of studies reporting outcomes of solid organ transplant recipients who received tixagevimab/cilgavimab found that the drug was well tolerated and a higher dose (300 mg/300 mg) was more protective against breakthrough infections and hospitalization than the lower dose (150 mg/150 mg). |
| Publish Date |
2025-11-19 05:57 |
| Citation |
El Chediak A, Ahuja D, Bruns C, Simard R, Spence K, Gul A, Forbes RC, Concepcion BP. Prophylactic role of tixagevimab/cilgavimab for COVID-19 in newly transplanted kidney recipients: Single-center experience and review of literature. World J Transplant 2025; 15(4): 100041 |
| URL |
https://www.wjgnet.com/2220-3230/full/v15/i4/100041.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v15.i4.100041 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
